Upsher Smith Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?
UPSHER SMITH LABS has ninety-one approved drugs.
There are eight US patents protecting UPSHER SMITH LABS drugs.
There are seventeen patent family members on UPSHER SMITH LABS drugs in ten countries and one hundred and thirty-seven supplementary protection certificates in thirteen countries.
Summary for Upsher Smith Labs
| International Patents: | 17 |
| US Patents: | 8 |
| Tradenames: | 70 |
| Ingredients: | 64 |
| NDAs: | 91 |
Drugs and US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-007 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | BETHANECHOL CHLORIDE | bethanechol chloride | TABLET;ORAL | 040635-001 | Jun 1, 2005 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | HALOPERIDOL | haloperidol | TABLET;ORAL | 211061-002 | Jan 8, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | ELIGLUSTAT TARTRATE | eliglustat tartrate | CAPSULE;ORAL | 212420-001 | May 2, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-002 | Mar 11, 2014 | AB2 | RX | Yes | No | 8,889,190 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Upsher Smith Labs | BRIMONIDINE TARTRATE AND TIMOLOL MALEATE | brimonidine tartrate; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 215598-001 | Dec 12, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
International Patents for Upsher Smith Labs Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3079703 | ⤷ Sign Up |
| South Korea | 101674509 | ⤷ Sign Up |
| Singapore | 11201604788U | ⤷ Sign Up |
| South Korea | 20160124930 | ⤷ Sign Up |
| South Korea | 20200010608 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2015089289 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Labs Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | CA 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| 0957929 | SPC/GB06/021 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
| 1409467 | 37/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
| 0637297 | C300054 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
